Phase 3 Results of Fixed -Dose Combination of Remogliflozin Etabonate and Vildagliptin in Indian T2DM Patients

被引：0
|
作者：
Mohan, Brij
Chawla, Manoj S.
Kodgule, Rahul R.
Tandon, Monika
Katare, Sagar
Suryawanshi, Sachin
Barkate, Hanmant V.
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-800-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
800-P
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real world assessment of effectiveness and safety of FDC of remogliflozin etabonate and Vildagliptin in T2DM patients
    Bhattacharyya, S.
    Katare, S.
    Khaladkar, K.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [2] Results of Randomized Double Blind Phase III trial of FDC of Remogliflozin Etabonate and Teneligliptin in T2DM patients
    Balamurgan, R.
    Mohan, B.
    Kodgule, R.
    Tandon, M.
    Pendse, A.
    Khaladkar, K.
    Sharath, R.
    Katare, S.
    Suryawanshi, S.
    Barkate, H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [3] A real-world clinical experience on effectiveness of remogliflozin etabonate in management of Indian patients with T2DM
    Mahapatra, H.
    Dalai, S.
    Sahoo, A.
    Khuntia, M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [4] Remogliflozin in Indian T2DM Patients: A Real-World Study
    Bhattacharya, Supratik
    Katare, Sagar
    DIABETES, 2020, 69
  • [5] A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV)
    Prabhat K Agarwal
    Divendu Bhushan
    Amit Bhate
    Sunil Naik
    Shailesh Adwani
    J S Kushwaha
    Sumit Bhushan
    Abhishek Mane
    Rujuta Gadkari
    Sanjay Choudhari
    Saiprasad Patil
    Hanmant Barkate
    Clinical Diabetes and Endocrinology, 10 (1):
  • [6] A Phase IV study to assess safety and efficacy of FDC of Remogliflozin, Metformin and Vildagliptin in management of T2DM
    Mane, A.
    Bhushan, S.
    Creado, S.
    Singh, G.
    Gadkari, R.
    Suryawanshi, S.
    Barkate, H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [7] First Human Dose Escalation Study with Remogliflozin Etabonate (RE) in Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus (T2DM)
    Kapur, Anita
    O'Connor-Semmes, Robin L.
    Hussey, Elizabeth K.
    Dobbins, Robert L.
    Tao, Wenli
    Hompesch, Marcus
    Nunez, Derek J.
    DIABETES, 2009, 58 : A136 - A136
  • [8] Combination Therapy of Canagliflozin and Teneligliptin in Japanese Patients with T2DM: Results from Phase 3 Studies
    Kaku, Kohei
    Kadowaki, Takashi
    Inagaki, Nobuya
    Kondo, Kazuoki
    Nishimura, Kenichi
    Kaneko, Genki
    Maruyama, Nobuko
    Nakanishi, Nobuhiro
    Iijima, Hiroaki
    Watanabe, Yumi
    Goda, Maki
    DIABETES, 2017, 66 : A319 - A319
  • [9] Comparison of Remogliflozin and Canagliflozin as Add-On Therapy in Indian Uncontrolled T2DM Subject
    Shankar, Anand
    DIABETES, 2020, 69
  • [10] Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)
    Fonseca, Vivian
    Dejager, Sylvie
    Albrecht, Diego
    Shirt, Lynda
    Schweizer, Anja
    DIABETES, 2006, 55 : A111 - A111
12345